Guardant Health grants 17,040 RSUs to executive

Monroe Terilyn J. reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Monroe Terilyn J. reported acquisition or exercise transactions in this Form 4 filing.

Guardant Health, Inc. reported that Chief People Officer Terilyn J. Monroe received a grant of 17,040 Restricted Stock Units on March 11, 2026. These RSUs represent the right to receive an equal number of Guardant common shares as they vest over time.

According to the award terms, 33% of the RSUs will vest on April 1, 2027, and the remaining 67% will vest in equal quarterly installments over the following two years. After this grant, Monroe holds 17,040 RSUs directly, reflecting a routine equity compensation award rather than an open‑market purchase or sale.

Insider Trade Summary

Grant/Award: 17,040 shares

Grant/Award 1 txn

Insider Monroe Terilyn J.

Role Chief People Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	17,040	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 17,040 contracts (Direct)

Footnotes (2)

1. F1. This represents a restricted stock unit award granted on March 11, 2026 that vests over a three-year period. 33% of the shares subject to such award will vest on April 1, 2027 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
2. F2. Not applicable for Restricted Stock Units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Guardant Health (GH) report for Terilyn J. Monroe?

Guardant Health reported that Chief People Officer Terilyn J. Monroe received a grant of 17,040 Restricted Stock Units. These RSUs are equity compensation and will convert into common shares only as they vest under the award’s schedule.

How many Restricted Stock Units did the Guardant Health (GH) executive receive?

Terilyn J. Monroe received 17,040 Restricted Stock Units. Each RSU represents a right to receive one share of Guardant Health common stock, subject to the vesting conditions and continued service requirements described in the award terms.

What is the vesting schedule of the new Guardant Health (GH) RSU grant?

The RSU award granted March 11, 2026 vests over three years. Thirty‑three percent will vest on April 1, 2027, and the remaining 67% will vest in equal quarterly installments over the subsequent two‑year period, assuming required conditions are satisfied.

Is the Guardant Health (GH) Form 4 transaction a stock purchase or sale?

The Form 4 reflects an RSU grant, not a market trade. It is classified as a grant or award acquisition with no open‑market buying or selling, and the reported price per unit is zero because it is compensation-based equity.

How many Guardant Health (GH) RSUs does Terilyn J. Monroe hold after this grant?

Following the reported transaction, Terilyn J. Monroe holds 17,040 Restricted Stock Units directly. These RSUs will settle into shares of Guardant Health common stock only as they vest under the specified three‑year vesting schedule described in the filing footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/13/2026 - 08:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Monroe Terilyn J.

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	03/11/2026		A		17,040		(1)	(2)	Common Stock	17,040	$0	17,040	D

Explanation of Responses:

1. This represents a restricted stock unit award granted on March 11, 2026 that vests over a three-year period. 33% of the shares subject to such award will vest on April 1, 2027 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Terilyn J. Monroe	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.